With a goal to offer a new standard in novel drug discovery using artificial intelligence (AI) technology, South Korea's Standigm Inc. is progressing multiple co-research projects with pharma and other partners, and is poised to establish a new laboratory facility this year to further validate the competitiveness of its AI-designed molecules.
Founded in 2015, privately-held Standigm has developed what it says is an automated and all-encompassing AI approach, using experts in...







